Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early Rheumatoid Arthritis

Rheumatoid Arthritis

The 20 year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis: Results from the Norfolk Arthritis Register

Arthritis Rheumatol.

Gwinnutt JM, Symmons DP, MacGregor AJ, Chipping JR, Marshall T, Lunt M, Verstappen SM

doi: 10.1002/art.40090.

COMMENTED

Rheumatoid Arthritis

Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA

Rheumatology (Oxford).

Stouten V, Westhovens R, Pazmino S, De Cock D, Van der Elst K, Joly J, Verschueren P, CareRA study group .

doi: 10.1093/rheumatology/

Rheumatoid Arthritis

Weight Change During the Early Rheumatoid Arthritis Period and Risk of Subsequent Mortality in Women With Rheumatoid Arthritis and Matched Comparators

Arthritis Rheumatol.

Sparks JA, Chang SC, Nguyen US, Barbhaiya M, Tedeschi SK, Lu B, Kreps DJ, Costenbader KH, Zhang Y, Choi HK, Karlson EW

doi: 10.1002/art.40346.

Rheumatoid Arthritis

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.

Ann Rheum Dis.

Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME

doi: 10.1136/

COMMENTED

Rheumatoid Arthritis

Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up

Ann Rheum Dis.

Poppelaars PB, van Tuyl LHD, Boers M

doi: 10.1136/annrheumdis-2018-214618.

Rheumatoid Arthritis

Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network

Rheumatology (Oxford).

Nikiphorou E, Norton SJ, Carpenter L, Walsh DA, Creamer P, Dixey J, Young A, Kiely PDW

doi: 10.1093/rheumatology/kez461.

Rheumatoid Arthritis

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial

Lancet.

Burmester GR, Buttgereit F, Bernasconi C, Álvaro-Gracia JM, Castro N, Dougados M, Gabay C, van Laar JM, Nebesky JM, Pethoe-Schramm A, Salvarani C, Donath MY, John MR, SEMIRA collaborators.

doi: 10.1016/S0140-6736(20)30636-X.

Rheumatoid Arthritis

Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis

Arthritis Res Ther.

Rydell E, Forslind K, Nilsson JÅ, Jacobsson LTH, Turesson C

doi: 10.1186/s13075-018-1575-2.

Rheumatoid Arthritis

Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritis

Rheumatology (Oxford).

Carpenter L, Nikiphorou E, Kiely PDW, Walsh DA, Young A, Norton S

doi: 10.1093/rheumatology/kez635.

Related content

The 20 year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis: Results from the Norfolk Arthritis Register

Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA

Weight Change During the Early Rheumatoid Arthritis Period and Risk of Subsequent Mortality in Women With Rheumatoid Arthritis and Matched Comparators

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.

Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up

Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial

Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis

Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritis